ATLAS-2M, Wk 96 Results: Long-Acting Injectable Cabotegravir + Rilpivirine Every 8 Wks Is Noninferior to Every 4 Wks

March 6-10, 2021; Virtual
Long-acting cabotegravir plus rilpivirine injections every 2 months are noninferior to monthly injections at Week 96 in virologically suppressed patients with no prior virologic failure.
Format: Microsoft PowerPoint (.ppt)
File Size: 172 KB
Released: March 11, 2021


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Download CCO slides reviewing data and guidelines on next-line ART for heavily-treatment experienced patients with HIV and multiclass drug resistance

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Released: April 19, 2021

Download CCO slides reviewing clinically relevant new data reported at CROI 2021 on a wide range of ART management topics.

Joseph J. Eron, Jr., MD Princy N. Kumar, MD, FIDSA, MACP Daniel R. Kuritzkes, MD Released: April 9, 2021

CCO commentary by Daniel R. Kuritzkes, MD, on emerging HIV treatment option data presented at CROI 2021

Daniel R. Kuritzkes, MD Released: April 6, 2021

CCO expert commentary by Dr. Darrell Tan on long-acting ART data presented at CROI 2021 and implications for clinical practice

person default Darrell H. S. Tan, MD, FRCPC, PhD Released: April 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.